one that is repressed during latency to one that is highly active following reactivation. Our work efficient reactivation from latency in hematopoietic cells. Herein, we show pharmacological 115 inhibition of AP-1 in the presence of reactivation stimuli decreases reactivation efficiency. 116
Additionally, mutation of the promoter proximal AP-1 binding site attenuates AP-1 recruitment to 117 the MIE enhancer and impairs reactivation following stimuli. Finally, our data reveal AP-1 118 recruitment to the MIE enhancer during reactivation is required to stimulate the expression of other IE genes or iP1-driven transcripts. Taken together, our results show AP-1 transactivation 121 of the MIE enhancer/promoter is an important factor for efficient HCMV reactivation from 122 latency. 123
124
Results 125
Pharmacological inhibition of c-fos suppresses viral reactivation in Kasumi-3 cells 126
We previously showed HCMV suppresses AP-1 activation to maintain latency (25) , which led us 127 to posit the requirement for this transcription factor's activation during reactivation from latency. 128
To test the impact AP-1 signaling has on reactivation, we infected Kasumi-3 cells with 129 TB40/EmCherry (WT) and cultured the cells in conditions favoring latency for 7 days (d) . 130
Cultures were then treated with vehicle (dimethylsulfoxide, DMSO) to maintain latency or 131 tetradecanoyl phorbol acetate (TPA) to induce reactivation for an additional 2 d in the presence 132 or absence of the c-fos inhibitor, T-5224, at a concentration we previously showed does not 133 impact cell viability (25) . We assessed the ability of each infection to reactivate by co-culturing 134 the infected Kasumi-3 cells with naïve fibroblasts and quantified infectious virus production by 135 Extreme Limiting Dilution Analysis (ELDA). As expected, TPA treatment of infected Kasumi-3 136 cells induced reactivation, as measured by an increase in virus production (28). However, 137 treatment with T-5224 attenuated virus production in TPA-treated cells (Fig. 1A) . We next 138 confirmed this finding using cord blood-derived, ex vivo cultured CD34 + HPCs, a natural site of 139 HCMV latency. We infected these primary cells with WT virus for 7 d under conditions favoring 140 latency, after which we cultured a portion of the infected cells in media that promotes 141 reactivation (29) either with or without T-5224. Similar to Kasumi-3 cells, our findings reveal 142 treatment with T-5224 reduced virus production in CD34 + HPCs treated with reactivation stimuli 143 ( Fig. 1B) . Together, these results indicate AP-1 activation is important for efficient reactivation 144 from latency. 145
Mutation of the promoter proximal AP-1 binding site in the MIE enhancer impairs viral 147 reactivation in hematopoietic cells 148
Based on our findings above, we next asked if AP-1 recruitment to the MIE enhancer aids in de-149 repressing the MIE locus during HCMV reactivation. To begin to investigate the contribution of 150 AP-1 to this process, we generated a recombinant virus in the bacterial artificial chromosome 151 (BAC)-derived, clinical isolate TB40/E (30), which we previously engineered to express mCherry 152 (TB40/EmCherry) (31). We disrupted the promoter proximal AP-1 binding site to generate 153 TB40/EmCherry-proximal-AP-1mutant (AP-1mut p ). Additionally, to ensure we did not introduce 154 off-site mutations during the recombineering process, we restored the mutated MIE 155 enhancer/promoter region to its wild type sequence to generate the repair virus, 156 TB40/EmCherry-proximal-AP-1repair (AP-1rep) (SI Appendix, Fig. S1 ). Consistent with previous 157 findings (26, 27), we confirmed AP-1mut p and AP-1rep display WT growth phenotypes in 158 fibroblasts (SI Appendix, Fig. S2A ). Similarly, both the mutant and repair viruses displayed WT 159 growth following lytic infection of epithelial cells (SI Appendix, Fig. S2B ). Together, these results 160 suggest AP-1 recruitment to the promoter proximal site is not required for efficient lytic 161
replication. 162
To determine the contribution of the AP-1 promoter proximal binding site during 163 reactivation from latency, we infected Kasumi-3 cells with WT, AP-1mut p , or AP-1rep for 7 d 164 under conditions favoring latency, after which we performed ELDA in the presence of vehicle or 165 TPA treatment. We found AP-1mut p -infected Kasumi-3 cells failed to efficiently reactivate to WT 166 or AP-1rep levels ( Fig. 2A) . Importantly, AP-1mut p -infected cells maintain comparable levels of 167 the viral genome compared to WT-or AP-1rep-infected cultures (SI Appendix, Fig. S3 ), 168 suggesting these infected cultures harbor latent virus. Similarly, the latency-associated gene, 169 UL138, was highly expressed relative to UL123 in all infected cultures, consistent with latent 170 infection (SI Appendix, Fig. S4 ). Treatment of each infected culture with TPA resulted in a 171 decrease in the ratio of UL138/UL123 (SI Appendix, Fig. S4 ), consistent with viral reactivation 172 (24, 25, 28) . The ratio of UL138:UL123 neared 1 in the WT-and AP-1rep-infected cells following 173 TPA treatment, which was significantly lower than the ratio of these transcripts in the AP-1mut p -174 infected counterpart cultures (SI Appendix, Fig. S4 ), suggesting inefficient reactivation of the 175 mutant virus. Consistent with these observations, AP-1mut p -infected primary CD34 + HPCs 176 produces significantly less infectious virus than either WT or AP-1rep when stimulated to 177 reactivate ( Fig. 2B ). Together, these data suggest AP-1mut p -infected hematopoietic cells 7 Finally, to distinguish between the relative contributions of AP-1 activity and the 180 requirement for the AP-1 promoter proximal binding site during reactivation from latency, we 181 evaluated viral reactivation in the presence or absence of the c-fos inhibitor, T-5224. To this 182 end, we infected Kasumi-3 cells with WT, AP-1mut p , or AP-1rep for 7 d under conditions 183 favoring latency. We then quantified infectious virus production by ELDA in the presence or 184 absence of TPA and/or T-5224. In the presence of T-5224, WT-and AP-1rep-infected cells fail 185 to efficiently reactivate virus, resulting in virion production similar to AP-1mut p -infected cells in 186 the absence of T-5224 treatment (Fig. 2C ). Further, T-5224 did not further impair reactivation of 187 the AP-1mut p virus. Taken together, these results demonstrate the importance of AP-1 188 activation and the requirement for the promoter proximal site of the MIE enhancer in promoting 189 HCMV reactivation. To test our hypothesis that AP-1 binds to the MIE enhancer, we first evaluated the recruitment 194 of the AP-1 subunits, c-fos and c-jun, to the enhancer region. We latently infected Kasumi-3 195 cells with WT, AP-1mut p , or AP-1rep for 7 d and then treated a portion of the infected cultures 196 for an additional 2 d with TPA treatment to induce reactivation. We then harvested the cultures 197 and performed chromatin immunoprecipitation (ChIP) assays to measure binding of c-fos and c-198 jun to the MIE enhancer. Our results show both c-fos and c-jun bind the MIE enhancer following 199 TPA treatment of WT, latently infected Kasumi-3 cells, although disruption of the promoter 200 proximal AP-1 site reduced recruitment of each AP-1 subunit ( Fig. 3 ). While both c-fos and c-jun 201 recruitment is significantly attenuated in the AP-1mut p -infected Kasumi-3 cells, our data reveal 202 neither AP-1 subunit is completely devoid of binding. This suggests AP-1 also binds the 203 promoter distal, non-consensus AP-1 binding site in the MIE enhancer region. Nonetheless, our 204
data collectively indicate the promoter distal AP-1 binding site plays a minor role in reactivation 205 from latency, as deletion of the promoter proximal site alone significantly impacts efficient 206 reactivation following stimuli ( Fig. 2A and B ) despite detectable promoter distal site binding of 207 AP-1 ( Fig. 3) . 208
209

AP-1 recruitment to the MIE enhancer during reactivation initiates MIE-driven gene 8
Together, our data reveal AP-1 recruitment to the promoter proximal site in the MIE enhancer is 212 an important determinant for efficient viral reactivation. Thus, we hypothesized this transcription 213 factor is critical for de-repression of UL122 and UL123 expression. In line with this, we posited 214 the recruitment of AP-1 to the MIE enhancer would not impact other IE genes. To this end, we 215 latently infected Kasumi-3 cells with WT, AP-1mut p , or AP-1rep for 7 d, after which we treated a 216 portion of the cells with TPA for an additional 2 d to stimulate reactivation. We then harvested 217 total RNA from the infected cultures and analyzed HCMV gene expression by RT-qPCR. We 218 assessed the MIE-driven transcripts UL122 and UL123, representative non-MIE-derived IE 219 genes (UL36, UL37), as well as a representative early (E; UL44) and late (L; UL99) transcript. 220 AP-1mut p -infected Kasumi-3 cells treated with TPA displayed attenuated UL122 and UL123 221 transcription compared to the WT-or AP-1rep-infected cultures ( Fig. 4A and B ). As expected, 222
this decreased E (UL44, Fig. 4E ) and L (UL99, Fig. 4F ) transcript abundance, whose 223 transactivation is dependent upon MIE-driven transcription and their subsequent translation 224 (32). However, transcription of UL36 and UL37, whose expression is not regulated by the MIE 225 enhancer, was unaffected by the mutation of the promoter proximal AP-1 site ( Fig. 4C and D) . are important for reactivation from latency (16). However, the contribution of transcription factor 236 binding on the activity of these alternative promoters during reactivation is unknown. To this 237 end, we infected Kasumi-3 cells as above and analyzed expression of MIE mRNAs by RT-238 qPCR, using primers specific for the transcripts derived from the dP, canonical MIEP, or the 239 internal promoters, iP1 and iP2 ( Fig. 5A ). Following TPA-induced reactivation of WT-infected 240 cultures, transcripts originating from each promoter increased ( Fig. 5B -E), concomitant with 241 UL122 (Fig. 4A ) and UL123 (Fig. 4B ) transcription. These findings are consistent with previous either WT or D, and E, respectively) . In contrast to these MIE-derived 245 transcripts, mRNA driven from the iP1 promoter was expressed to similar levels following 246 reactivation when compared to WT-or AP-1rep-infected cultures (Fig. 5C ), suggesting iP1-247 driven transcription is independent of AP-1 binding to the promoter proximal site in the MIE 248 enhancer. Taken together, these data suggest AP-1 binding to the MIE enhancer facilitates the 249 expression of MIEP-, iP2-, and dP-derived transcripts, while iP1-driven transcription remains 250 independent of AP-1 recruitment to this region. 251 252 Discussion 253 HCMV reactivation is a multifaceted process, requiring de-repression of UL122 and UL123 254 transcription, changes in transcription factor binding, as well as changes in chromatin structure 255 to promote transcription (17). In this study, we found AP-1 binding to the MIE enhancer is critical 256
for the re-expression of both UL122 and UL123, as well as HCMV reactivation. 257
Pharmacological inhibition of c-fos, a component of AP-1, significantly reduced the reactivation 258 efficiency of WT-infected hematopoietic cells (Fig. 1) . Similarly, disruption of the promoter 259 proximal AP-1 binding site within the MIE enhancer attenuated HCMV reactivation (Fig. 2) . Our 260 data demonstrate AP-1 is recruited to the MIE enhancer following reactivation of WT virus, and 261 mutation of the promoter proximal AP-1 binding significantly decreases AP-1 binding (Fig. 3) . 262
Further, while the MIE enhancer has two AP-1 binding sites, our data emphasize the promoter 263 proximal site is critical for viral reactivation (Fig. 2, 3) . AP-1 recruitment to the MIE enhancer 264 aids in the transactivation of the MIE-driven IE genes, UL122 and UL123, while IE genes not 265 derived from the MIE region, including UL36 and UL37, remain unaffected (Fig. 4) . Importantly, 266
AP-1 binding to its promoter proximal site in the MIE enhancer activates transcription from the 267 canonical MIEP, as well as the alternative iP2 and dP promoters, while iP1 activity is AP-1-268 independent (Fig. 5 ). Together, our results reveal a mechanism by which the AP-1 transcription 269 factor binds the MIE enhancer to activate multiple promoters in the MIE locus, thereby 270 contributing to successful reactivation of HCMV from latency. 271
While viral reactivation is likely multifactorial, it is clear c-fos and c-jun are critical 272 components of this process. Our previous findings showed pUS28 attenuates c-fos expression 273 and activation, concomitant with reduced AP-1 recruitment to the MIE enhancer during latency latency (33), although this is not contingent upon pUS28 expression or function (25). These 276 findings suggest HCMV has adapted independent mechanisms to attenuate the two subunits 277 comprising AP-1 to prevent its binding to the MIE enhancer during latency. 278
Our findings also suggest HCMV evolved sites for AP-1 recruitment to the MIE enhancer 279 region for viral reactivation, although this association is not required for efficient lytic replication. 280 This is not unprecedented, as similar mechanisms were described for the CRE response 281 elements (19, 34) . Consistent with this, several groups have shown AP-1 binds to and activates 282 the MIE enhancer/promoter in in vitro expression assays (26, 34, 35) . In agreement with our 283 results herein, AP-1 is recruited to the MIE enhancer in a murine model of allograft-induced 284 murine CMV (MCMV) reactivation (36). Furthermore, work from Isern, et al, revealed disruption 285 of both AP-1 binding sites within the MIE enhancer region had no effect on HCMV lytic 286 replication in fibroblast and epithelial cells (26), consistent with our current findings. There is, 287 however a notable difference between this study and ours. Isern, et al. generated a chimeric 288 MCMV, replacing the native murine MIE enhancer with the HCMV enhancer region, and then 289 disrupted both AP-1 binding sites. Using this chimeric recombinant in either lung or spleen 290 explants of neonatal mice, they found no difference in virus reactivation relative to infection with 291 a chimeric virus containing wild type AP-1 binding sites (26). While this work revealed no role for 292 the promoter proximal AP-1 binding site, there are significant differences in the experimental 293 models we employed herein and the chimeric MCMV-infected mouse models used in the 294 previously published study (26) . 295
In addition to HCMV, other herpesviruses modulate AP-1 during infection. The Epstein 296
Barr virus (EBV) protein, BGLF2, and the Kaposi's sarcoma-associated herpesvirus (KSHV)-297 encoded ORF45 both activate the AP-1 signaling pathway to promote viral gene expression, 298 replication, and survival (37, 38) . EBV also encodes an AP-1 homolog, BZLF1, which, like AP-1, 299 supports resting B cell proliferation and binds methylated EBV promoters critical for reactivation 300 (39). Murine gammaherpesvirus 68 (MHV68) expresses the microRNA mghv-miR-M1-1, which 301 downregulates c-jun and subsequent AP-1 activation, resulting in the suppression of viral lytic 302 replication (40). Together, these results show controlling AP-1 is a common strategy among 303
herpesviruses, suggesting targeting this transcription factor could prove beneficial for 304 suppressing reactivation and subsequent disease associated with a variety of herpesviruses. iP1-and iP2-derived transcripts for viral reactivation (16). Our findings build upon these 307 observations and begin to unravel the likely complex web of transcription factors that regulate the iP1 and iP2 promoters. We found AP-1 recruitment to the promoter proximal site within the 309 MIE enhancer drives transcription from the MIEP, iP2, and dP (Fig. 5B, D, and E, respectively) . 310
However, transcription from iP1 is independent of AP-1 recruitment to the promoter proximal 311 site within the MIE enhancer, as the AP-1mut p -infected cells express iP1-driven transcripts to 312 levels similar to those we observed in WT-infected cells (Fig. 5C ). This finding suggests iP1-313 driven transcription alone is not sufficient to drive reactivation, as AP-1mut p -infected cells fail to 314 efficiently produce infectious virus following the addition of reactivation stimuli (Fig. 2) . This 315 result also suggests additional transcription factors or chromatin remodeling proteins may 316 alternatively control iP1 activity, further highlighting the complexity in the regulation of 317 transcription in MIE locus. 318
How is AP-1 activated in response to cues that reactivate HCMV? Elucidating the 319 precise biological mechanism could indeed reveal potential therapeutic targets one could exploit 320
to prevent viral reactivation. Two pathways that activate AP-1, Src-ERK (41) and PI3K/Akt (42), 321 are already implicated in HCMV reactivation (17, 20) and are therefore potential candidates for 322 further investigation. As a potent signaling molecule, US28 is an attractive, latently expressed 323 viral protein capable of modulating cellular signaling pathways such as these. While our 324 previous data showed US28 attenuates c-fos expression and activity as well as AP-1 binding to 325 the MIE enhancer during latency (25), it remains unknown how US28 signaling is modified to 326 favor reactivation rather than latent conditions. It is attractive to hypothesize an additional viral 327 or cellular protein is triggered to alter US28's behavior following reactivation stimuli, though 328 additional work is needed to realize such mechanistic nuances. It is also possible AP-1 recruits 329 other factors, such as histone acetyltransferases (HATs) (43) to facilitate chromatin remodeling 330 and/or other transcription factors (e.g. CREB and NFκB), all of which would contribute to de-331 repression of MIE promoters (13). Finally, c-fos and c-jun functional activity contribute to 332 myeloid differentiation and function in response to pro-inflammatory stimuli (44). These 333 possibilities present numerous avenues for future research aimed at understanding the 334 underlying biological mechanisms regulating AP-1 activation and its transactivation of the MIE 335 enhancer/promoter region. 336
Our findings detailed herein reveal AP-1 activation is critical for HCMV reactivation. AP-1 337 recruitment to its promoter proximal site within the MIE enhancer activates multiple MIE 338 promoters, including the dP, MIEP, and iP2, to drive MIE transcription, which overall facilitates and reactivation that will lead to the development of novel therapies to prevent viral reactivation 342 in vulnerable patients. Isolation of CD34 + HPCs is described in detail elsewhere (45). Immediately following 362 isolation, CD34 + HPCs were infected at a multiplicity of 2.0 TCID 50 /cell, as previously described 363 (24, 28, 46) standard deviation of three biological replicates. The statistical significance was calculated using 540 two-way ANOVA followed by Tukey's post-hoc analysis. *p<0.05, **p<0.01, ***p<0.001, and ns 541 = not significant 542 RTqPCR and is shown relative to cellular GAPDH. Each data point (circles) is the mean of 3 577 technical replicates, and the error bars indicate standard deviation of three biological replicates. 578
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